retatrutide 2024 ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial The Retatrutide Strategy No One

Standard semaglutide or tirzepatide pens are available with a fixed strength

A meta-analysis that combined data from systematic reviews and meta-analyses came to the conclusion that there was likely no increase in the risk of diabetic retinopathy from any of the diabetes drugs.[ref] However, this is still a side effect to be aware of and talk with your doctor about your individual risk

Food is medicine

doi: 10.1016/S0165-1838(96)00071-9 166 DruckerDJBuseJBTaylorKKendallDMTrautmannMZhuangDet al

That receptor isn't accessible from the gut lumen

Gradual Dose Escalation Starting at the lowest effective dose and increasing gradually gives the body time to adapt